Compare Gigacloud Technology Inc (GCT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gigacloud Technology Inc trades at $55.7 (market cap $2.02B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 63.1× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GCT | VRTX | |
|---|---|---|
Market Cap | $2.02B | $127.55B |
Volume | 1,020,985 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $56.42 | $557.96 |
52-Week Low | $25.46 | $407.37 |
Typical Hold Time | 21 Days | 120 Days |
Enterprise Value | $2.14B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $55.96, up 2.19% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 27.6% YoY revenue growth in Q2 2026. Recent news highlights institutional interest and European expansion driving optimism.
The outlook remains positive with 66.7% analyst buy ratings and a $32.50 consensus target, though RSI levels suggest potential near-term consolidation. Key risks include insider selling activity and market volatility, but strong cash flow generation and disciplined expansion support long-term growth prospects.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
